Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts

References

• Boulle A, Davies M-A, Hussey H, Ismail M, Morden E, Vundle Z, Zweigenthal V, Mahomed H, Paleker M, Pienaar D. Western cape department of health in collaboration with the national institute for communicable diseases, South Africa. Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis. 2021;73(7):e2005–9. doi:10.1093/cid/ciaa1198.
   PubMedGoogle Scholar
• Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, Eggo RM, Morton CE, Bacon SCJ, Inglesby P, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021;8(1):e24–32. doi:10.1016/S2352-3018(20)30305-2.
   PubMed Web of Science ®Google Scholar
• Kamis KF, Barbera L, Abdo M, Rowan SE, Hussain C, Gardner EM, Johnson SC, MaWhinney S, Davis AJ, Carlson J, et al. Risk factors for hospitalization in people with HIV and COVID-19. J Acquir Immune Defic Syndr. 2021;88(3):e22. doi:10.1097/QAI.0000000000002780.
   PubMed Web of Science ®Google Scholar
• Shapiro AE, Bender Ignacio RA, Whitney BM, Delaney JA, Nance RM, Bamford L, Wooten D, Keruly JC, Burkholder G, Napravnik S, et al. Factors associated with severity of COVID-19 disease in a multicenter cohort of people with HIV in the United States, March–December 2020. J Acquir Immune Defic Syndr. 2022;90(4):369–76. doi:10.1097/QAI.0000000000002989.
   PubMed Web of Science ®Google Scholar
• Lb B, Ma S, G M. The interplay between HIV and COVID-19: summary of the data and responses to date. Curr Opin HIV AIDS [Internet]. 2021 [cited 2023 Sep 28]; 16. https://pubmed.ncbi.nlm.nih.gov/33186229/.
   Web of Science ®Google Scholar
• Dandachi D, Geiger G, Montgomery MW, Karmen-Tuohy S, Golzy M, Antar AAR, Llibre JM, Camazine M, Díaz-De Santiago A, Carlucci PM, et al. Characteristics, comorbidities, and outcomes in a multicenter registry of patients with HIV and coronavirus disease-19. Clin Infect Dis. 2021;73(7):e1964–72. doi:10.1093/cid/ciaa1339.
   PubMed Web of Science ®Google Scholar
• Spinelli MA, Lynch KL, Yun C, Glidden DV, Peluso MJ, Henrich TJ, Gandhi M, Brown LB. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. Lancet HIV. 2021;8(6):e334–41. doi:10.1016/S2352-3018(21)00072-2.
   PubMed Web of Science ®Google Scholar
• Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23(22):2902–8. doi:10.1016/j.vaccine.2004.11.057.
   PubMed Web of Science ®Google Scholar
• Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, McCutchan JA, Deresinski SC, California Collaborative Treatment Group. Safety and immunogenicity of hepatitis a vaccine in human immunodeficiency virus–infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis. 2003;187(8):1327–31. doi:10.1086/374562.
   PubMed Web of Science ®Google Scholar
• Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, van Dissel JT. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS. 1998;12(17):F217–223. doi:10.1097/00002030-199817000-00002.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, Faix D, Defang G, Bai Y, Iverson E, Lalani T, et al. Immunogenicity of a monovalent 2009 influenza a (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-Infected adults with HIV-Uninfected adults. Clin Infect Dis. 2011;52(1):138–46. doi:10.1093/cid/ciq019.
   PubMed Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS. 1994;8(4):469–76. doi:10.1097/00002030-199404000-00008.
   PubMed Web of Science ®Google Scholar
• Wallace MR, Brandt CJ, Earhart KC, Kuter BJ, Grosso AD, Lakkis H, Tasker SA. Safety and immunogenicity of an inactivated hepatitis a vaccine among HIV-infected subjects. Clin Infect Dis. 2004;39(8):1207–13. doi:10.1086/424666.
   PubMed Web of Science ®Google Scholar
• Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med. 1988;109(2):101–5. doi:10.7326/0003-4819-109-2-101.
   PubMed Web of Science ®Google Scholar
• Tantawichien T, Jaijaroensup W, Khawplod P, Sitprija V. Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Clin Infect Dis. 2001;33(10):E122–124. doi:10.1086/324087.
   PubMed Web of Science ®Google Scholar
• Bertolini DV, Costa LS, van der Heijden IM, Sato HK, Marques HDS. Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults. Vaccine. 2012;30(37):5482–6. doi:10.1016/j.vaccine.2012.06.069.
   PubMed Web of Science ®Google Scholar
• Tasker SA, O’Brien WA, Treanor JJ, Weiss PJ, Olson PE, Kaplan AH, Wallace MR. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine. 1998;16(9–10):1039–42. doi:10.1016/S0264-410X(97)00275-2.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Teruya K, Tanaka M, Kikuchi Y, Takahashi T, Kimura S, Oka S, HIV/Influenza Vaccine Study Team. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39:167–73.
   PubMed Web of Science ®Google Scholar
• Teshale EH, Hanson D, Flannery B, Phares C, Wolfe M, Schuchat A, Sullivan P. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998–2003. Vaccine. 2008;26(46):5830–4. doi:10.1016/j.vaccine.2008.08.032.
   PubMed Web of Science ®Google Scholar
• Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, Huppert A, Mor O, Goldstein M, Levin EG, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect. 2021;27(12):1851–5. doi:10.1016/j.cmi.2021.07.031.
   PubMed Web of Science ®Google Scholar
• Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, Lanini S, De Pascale L, Matusali G, Mariotti D, et al. Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current CD4 T-Lymphocyte count. Clin Infect Dis. 2022;75(1):e552–63. doi:10.1093/cid/ciac238.
   PubMed Web of Science ®Google Scholar
• Hensley KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, Mueller YM, Dalm VASH, Papageorgiou G, Steggink H, Gorska A, Bogers S, et al. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: a nationwide prospective cohort study. PLoS Med. 2022;19(10):e1003979. doi:10.1371/journal.pmed.1003979.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD, Dheda K, Barnabas SL, Bhorat QE, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021;8(9):e568–80. doi:10.1016/S2352-3018(21)00157-0.
   PubMed Web of Science ®Google Scholar
• Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, Alagaratnam J, Aley PK, Ali M, Ansari MA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021;8(8):e474–85. doi:10.1016/S2352-3018(21)00103-X.
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhang Y, He Z, Huang H, Tian X, Wang G, Chen D, Ren Y, Jia L, Wang W, et al. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study. EClinicalMedicine. 2022;43:101226. doi:10.1016/j.eclinm.2021.101226.
   PubMedGoogle Scholar
• Lv Z, Li Q, Feng Z, Zheng X, Null N, Yang H, Gu Q, Ying S, Qi Y, Li X, et al. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV. Int Immunopharmacol. 2022;102:108383. doi:10.1016/j.intimp.2021.108383.
   PubMed Web of Science ®Google Scholar
• Zou S, Wu M, Ming F, Wu S, Guo W, Marley G, Xing Z, Zhang Z, Zeng M, Sun C, et al. Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals. AIDS Res Ther. 2022;19(1):33. doi:10.1186/s12981-022-00459-y.
   PubMed Web of Science ®Google Scholar
• Department of Disease Control. COVID-19 vaccination guidelines under pandemic B.E.2564, Thailand [Internet]; 2021. https://www.ddc.moph.go.th/uploads/files/1729520210301021023.pdf.
   Google Scholar
• Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, Jentzsch S, Helbig ET, Lippert LJ, Tscheak P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021;9(11):1255–65. doi:10.1016/S2213-2600(21)00357-X.
   PubMed Web of Science ®Google Scholar
• Yorsaeng R, Vichaiwattana P, Klinfueng S, Wongsrisang L, Sudhinaraset N, Vongpunsawad S, Poovorawan Y. Immune response elicited from heterologous SARS-CoV-2 vaccination: sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria) [Internet]. 2021 [cited 2023 Jan 2];2021.09.01.21262955. doi:10.1101/2021.09.01.21262955v1.
   Google Scholar
• Roche Diagnostics. Elecsys® anti-SARS-cov-2 S [Internet]. https://www.fda.gov/media/144037/download.
   Google Scholar
• GenScript USA Inc. cPassTM SARS-CoV-2 neutralization antibody detection kit [Internet]. https://www.fda.gov/media/143583/download.
   Google Scholar
• De Santis GC, Mendrone A, Langhi D, Covas DT, Fabron A, Cortez AJP, Dinardo CL, Ubiali EMA, Marques JFC, Bordin JO, et al. Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19. Hematol Transfus Cell Ther. 2021;43(2):212–3. doi:10.1016/j.htct.2021.03.001.
   PubMedGoogle Scholar
• Huang X, Yan Y, Su B, Xiao D, Yu M, Jin X, Duan J, Zhang X, Zheng S, Fang Y, et al. Comparing immune responses to inactivated vaccines against SARS-CoV-2 between people living with HIV and HIV-Negative individuals: a cross-sectional study in China. Viruses. 2022;14(2):277. doi:10.3390/v14020277.
   PubMed Web of Science ®Google Scholar
• Spinelli MA, Peluso MJ, Lynch KL, Yun C, Glidden DV, Henrich TJ, Deeks SG, Gandhi M. Differences in post-mRNA vaccination severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) concentrations and surrogate virus neutralization test response by human immunodeficiency virus (HIV) status and type of vaccine: a matched case-control observational study. Clin Infect Dis. 2021;75:e916–9.
   Web of Science ®Google Scholar
• Hassold N, Brichler S, Ouedraogo E, Leclerc D, Carroue S, Gater Y, Alloui C, Carbonnelle E, Bouchaud O, Mechai F, et al. Impaired antibody response to COVID-19 vaccination in advanced HIV infection. AIDS. 2022;36(4):F1. doi:10.1097/QAD.0000000000003166.
   PubMed Web of Science ®Google Scholar
• Kardava L, Moir S. B-cell abnormalities in HIV-1 infection: roles for IgG3 and T-bet. Curr Opin HIV AIDS. 2019;14(4):240–5. doi:10.1097/COH.0000000000000547.
   PubMed Web of Science ®Google Scholar
• Titanji K, De Milito A, Cagigi A, Thorstensson R, Grützmeier S, Atlas A, Hejdeman B, Kroon FP, Lopalco L, Nilsson A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood. 2006;108(5):1580–7. doi:10.1182/blood-2005-11-013383.
   PubMed Web of Science ®Google Scholar
• Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O, Cox AL, Blankson JN. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV). Clin Infect Dis. 2021;74(7):1268–70. doi:10.1093/cid/ciab648.
   Web of Science ®Google Scholar
• Lombardi A, Butta GM, Donnici L, Bozzi G, Oggioni M, Bono P, Matera M, Consonni D, Ludovisi S, Muscatello A, et al. Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study. Lancet Reg Health Eur. 2022;13:100287. doi:10.1016/j.lanepe.2021.100287.
   PubMedGoogle Scholar
• Benet S, Blanch-Lombarte O, Ainsua-Enrich E, Pedreño-Lopez N, Muñoz-Basagoiti J, Raïch-Regué D, Perez-Zsolt D, Peña R, Jiménez E, de la Concepción MLR, et al. Limited humoral and specific T-Cell responses after SARS-CoV-2 vaccination in PWH with poor immune reconstitution. J Infect Dis. 2022;226(11):1913–23. doi:10.1093/infdis/jiac406.
   PubMed Web of Science ®Google Scholar
• Wong NS, Wong BCK, Chan JMC, Wong KH, Tsang OTY, Mok CKP, Hui DSC, Lee SS, Chan DPC. Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine. AIDS. 2022;36(9):1255–64. doi:10.1097/QAD.0000000000003237.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, Groome MJ, Huppert A, O’Brien KL, Smith PG, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–44. doi:10.1016/S0140-6736(22)00152-0.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Nason MC, Flach B, Gagne M, O’Connell S, Johnston TS, Shah SN, Edara VV, Floyd K, Lai L, et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science. 2021;373(6561):eabj0299. doi:10.1126/science.abj0299.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• López-Cortés LF, Saborido-Alconchel A, Trujillo-Rodríguez M, Serna-Gallego A, Llaves-Flores S, Muñoz-Muela E, Pérez-Santos MJ, Lozano C, Mejias-Trueba M, Roca C, et al. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered. Front Immunol. 2023;14:1129753. doi:10.3389/fimmu.2023.1129753.
   PubMed Web of Science ®Google Scholar
• Yang Z-R, Jiang Y-W, Li F-X, Liu D, Lin T-F, Zhao Z-Y, Wei C, Jin Q-Y, Li X-M, Jia Y-X, et al. Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. Lancet Microbe. 2023;4(4):e236–46. doi:10.1016/S2666-5247(22)00390-1.
   PubMedGoogle Scholar
• Lang R, Humes E, Coburn SB, Horberg MA, Fathi LF, Watson E, Jefferson CR, Park LS, Gordon KS, Akgün KM, et al. Analysis of severe illness after postvaccination COVID-19 breakthrough among adults with and without HIV in the US. JAMA Netw Open. 2022;5(10):e2236397. doi:10.1001/jamanetworkopen.2022.36397.
   PubMed Web of Science ®Google Scholar
• Chambers C, Samji H, Cooper CL, Costiniuk CT, Janjua NZ, Kroch AE, Arbess G, Benoit AC, Buchan SA, Chung H, et al. Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV. AIDS. 2022;36(15):F17–26. doi:10.1097/QAD.0000000000003405.
   PubMed Web of Science ®Google Scholar
• Bekker L-G, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, Kassanjee R, Collie S, Sanne I, Boulle A, et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022;399(10330):1141–53. doi:10.1016/S0140-6736(22)00007-1.
   PubMed Web of Science ®Google Scholar